Features:

Manufactured by Siemens, the DCA Vantage® is an FDA approved analyzer that helps monitor glycemic control and detect early kidney disease in environments ranging from the physician’s office to remote, point-of-care coordinated sites in hospitals and multisite practices. By offering unparalleled precision, accuracy, and ease to monitor glucose levels, the DCA Vantage allows physicians to manage diabetes patients more effectively. This advanced point-of-care analyzer makes consultations easier by monitoring glycemic control and diabetes complications.

The DCA Vantage® analyzer offers ease of use, powerful functionality, versatile data management, and reporting options to suit different test environments and workloads. Users can meet lab-quality testing standards with this analyzer. It speeds and simplifies diabetes tests and delivers accurate, clinically relevant results to improve decision-making, patient compliance, and outcomes.

Self-contained cartridges facilitate easy walkaway operation after sample loading, with no sample or reagent preparation. The device also comes with a bar-code scanner which minimizes transcription errors and generates an audible alert to confirm a successful scan. Maintenance requirements are minimal and automatic reminders alert when maintenance is due. Other features include

• Onboard GFR calculator that indexes kidney function
• Flexible patient trending graphs and patient result recording options
• Convenient local storage of up to 4,000 onboard records with powerful sorting capabilities
• No sample or reagent preparation required
• Automatically upload results and QC information to LIS/HIS to reduce manual logging and save time

Its customizable security access modes support up to 1,000 operators, protect patient information, and prevent operation by unauthorized users. Reliable lab equipment suppliers offer leasing plans and reagent rental agreements for this analyzer, both great options for labs with budget constraints.

With the increasing incidence of Type 2 diabetes, the volume of HbA1c testing conducted by clinical laboratories has increased dramatically in recent times. Numerous point-of-care analyzers are available in the market today for fast and reliable HbA1c testing. The DCA® Vantage analyzer from Siemens Healthineers is an advanced model that quantitatively measures HbA1c in blood and detects early kidney disease.

The DCA Vantage Analyzer simplifies diabetes testing, delivering accurate, clinically relevant results during the patient visit to help physicians and nurses improve patient decision-making and diabetic patient compliance. This analyzer supports lab managers with its ease of use, powerful functionality, versatile data management, and reporting options to suit different test environments and workloads. The device provides fast results for HbA1c from a whole blood sample in six minutes, minimizing the need for follow-up visits. The unit also detects Albumin, Creatinine, and Albumin-to-Creatinine (A:C) ratio from a urine specimen in 7 minutes to report a quantitative protein status with automatic creatinine adjustment.

This unit’s bar-code scanner minimizes transcription errors, and generates an audible alert to confirm a successful scan. Other key features –

• Convenient local storage of up to 4,000 onboard records with powerful sorting capabilities
• Automatic upload of patient/QC results and information
• Bar-code scanner for safer and faster patient/operator ID entry
• Intuitive color touch screen display
• Onboard GFR calculator indexes kidney function
• Self-contained immunoassay cartridges
• Minimal maintenance requirements

Supported by the RAPIDComm® Data Management System, this analyzer can remotely manage multiple analyzers and operators to enhance compliance and improve risk management. POC coordinators can standardize test procedures, enforce QC protocols, control access privileges, define operator recertification requirements, and more. Customized alerts, reports, and audit trails ensure peace of mind.

In May 2018, Siemens Healthineers and Hill-Rom had signed a co-marketing agreement to provide a suite of point-of-care diagnostic instruments that will enable primary healthcare providers in the U.S. to bridge gaps in diabetes care and satisfy value-based quality measures in a single office visit. This integrated offering includes the Siemens Healthineers DCA Vantage® Analyzer for HbA1c testing, the CLINITEK Status®+ Urine Chemistry Analyzer for kidney checks, and Hill-Rom’s Welch Allyn® RetinaVue® Network and imaging technology for teleretinal exams.

Specifications: